Mereo BioPharma Group plc
http://mereobiopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mereo BioPharma Group plc
Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders
Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.
Missed Opportunities: Why Small Biotech Needs To Plan Ahead For Global Reach
If small biotech does more to plan ahead for ex-US market requirements, companies and their investors – and crucially patients – will benefit.
Pharma Outlook 2022: What Next After A Year Of Innovation And Growth?
The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?
Asher Bio Raises $108m For Immune Cell-Specific Therapies
With a CD8-targeting IL-2 mutein as its lead program, the start-up is developing cis-targeted immunotherapies that selectively target two molecules on the same immune cell for improved efficacy and safety.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Mereo BioPharma Group Ltd.
- Mereo BioPharma Group plc (MPH:LN)
- OncoMed Pharmaceuticals, Inc. (OMED)